Qualigen Therapeutics, Inc. announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company's in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this platform's lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.309 USD | +7.29% | +10.28% | -43.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.82% | 1.82M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302